Get the Stockscreener App
1.43
1.77%
0.02
Allarity Therapeutics Inc stock is traded at $1.43, with a volume of 114.65K.
It is up +1.77% in the last 24 hours and down -18.47% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
See More
Previous Close:
$1.41
Open:
$1.43
24h Volume:
114.65K
Relative Volume:
0.09
Market Cap:
$1.96M
Revenue:
-
Net Income/Loss:
$-11.90M
P/E Ratio:
-0.00596
EPS:
-239.88
Net Cash Flow:
$-12.75M
1W Performance:
-7.42%
1M Performance:
-18.47%
6M Performance:
+43.50%
1Y Performance:
-87.19%
1-Day Range:
$1.37
$1.445
1-Week Range:
$1.26
$1.55
52-Week Range:
$0.1131
$22.20
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Allarity Therapeutics Inc Stock (ALLR) Latest News
Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire
DEADLINE ALERT for WBTN, GTLB, ALLR, and COIN: The Law - GlobeNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALLR 截止日期通知：全球領先的律師事務所 ROSEN 鼓勵 Allarity Therapeutics, Inc. 投資者在證券集體訴訟的重要截止日期 11 月 12 日 之前聘請律師 - GlobeNewswire Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesALLR - PR Newswire
Allr Deadline Notice: Rosen, A Global And Leading Law Firm, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – ALLR - Wahanariau
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Allarity Therapeutics to Contact Us to Have Their Losses Evaluated Today - GlobeNewswire Inc.
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, I - GuruFocus.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - Markets Insider
ALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Allarity Therapeutics stock hits 52-week low at $1.32 amid steep decline By Investing.com - Investing.com South Africa
Allarity Therapeutics stock hits 52-week low at $1.32 amid steep decline - Investing.com India
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
ALLR FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
Allarity Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming DeadlinesALLR - PR Newswire
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Allarity Therapeutics, Inc. to Contact the Firm Today! - AccessWire
Allarity Therapeutics, Inc Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Allarity Therapeutics, - AccessWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Agenus, and New Fortress and Encourages Investors to Contact the Firm - ForexTV.com
Allarity Vaults on Patent Tidings - Baystreet.ca
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib - The Manila Times
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
RLF, TRUSTED INVESTOR COUNSEL, Encourages Allarity - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - PR Newswire
Indo-Asian News Service - IANS India Pvt Ltd
Faruqi & Faruqi Reminds Allarity Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 12, 2024ALLR - AccessWire
Allarity Therapeutics, Inc. Class Action Alert: Wolf - GlobeNewswire
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Allarity - GlobeNewswire
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to - The Bakersfield Californian
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):